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A B S T R A C T
DNA-protein crosslinks (DPCs) are a speciﬁc type of DNA lesion consisting of a protein covalently and irre-
versibly bound to DNA, which arise after exposure to physical and chemical crosslinking agents. DPCs can be
bulky and thereby pose a barrier to DNA replication and transcription. The persistence of DPCs during S phase
causes DNA replication stress and genome instability. The toxicity of DPCs is exploited in cancer therapy: many
common chemotherapeutics kill cancer cells by inducing DPC formation.
Recent work from several laboratories discovered a specialized repair pathway for DPCs, namely DPC pro-
teolysis (DPCP) repair. DPCP repair is carried out by replication-coupled DNA-dependent metalloproteases: Wss1
in yeast and SPRTN in metazoans. Mutations in SPRTN cause premature ageing and liver cancer in humans and
mice; thus, defective DPC repair has great clinical ramiﬁcations. In the present review, we will revise the current
knowledge on the mechanisms of DPCP repair and on the regulation of DPC protease activity, while highlighting
the most signiﬁcant unresolved questions in the ﬁeld. Finally, we will discuss the impact of faulty DPC repair on
disease and cancer therapy.
1. Introduction
DNA-protein crosslinks (DPCs) are frequent and particularly toxic
DNA lesions, as they impede essential DNA transactions. They consist of
a protein covalently and irreversibly bound to DNA. DPCs can arise
after exposure to physical, chemical or chemotherapeutic agents and
through the faulty action of certain DNA metabolizing enzymes [1].
Physical agents include ionizing radiation (IR), which target DNA and/
or proteins generating reactive radicals, and UV light, which excites
DNA bases that react with amino acids. Chemical crosslinking is caused
by metals and aldehydes; aldehydes act by crosslinking the amino and
imino groups from amino acid side chains and DNA bases to one an-
other. Aldehydes are released during lipid peroxidation (e.g. mal-
ondialdehyde), histone demethylation (formaldehyde) and alcohol
breakdown, implying that threats posed by DPCs are ubiquitous [2,3];
indeed, aldehydes are also present in the environment (e.g. cosmetics).
Additional sources of DPCs are abasic sites within nucleosomes [4].
Some enzymes form a transient covalent intermediate with DNA as part
of their catalytic cycle; this covalent intermediate can be stabilized in
the presence of, e.g., a distortion on DNA or speciﬁc poisons, resulting
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in an abortive reaction and trapping of the protein in a DPC. These
DPCs are classiﬁed as enzymatic DPCs, as opposed to the formerly de-
scribed and more general non-enzymatic DPCs [5] (Fig. 1). A renowned
case of enzymatic DPC forms following exposure of Topoisomerase 1 to
Topoisomerase 1-speciﬁc poisons called camptothecins (namely Top1
cleavage complex, or Top1-cc), which are widely used in cancer therapy
for their cytotoxicity [6].
Mammalian cells are challenged with approximately 6000 DPCs
during exponential growth [7]. The chromatin environment is generally
crowded and exposed to a variety of crosslinking agents, meaning any
protein in the vicinity of DNA can potentially be crosslinked to DNA.
Considering their bulky nature, DPCs present major barriers, especially
to DNA replication and transcription [1], ultimately causing DNA re-
plication stress and genomic instability; therefore, DPC removal is es-
sential for cell survival [8].
Recently, the eﬀort of several laboratories has brought a new
pathway to the attention of the DNA repair ﬁeld. This repair mechanism
is speciﬁc for DPCs and is carried out by replication-coupled DNA-de-
pendent proteases in eukaryotes. DPC proteolysis repair has great
medical signiﬁcance since defective DPC protease activity is associated
with progeria and cancer predisposition in humans and mice. We will
review the current knowledge on DPC repair and discuss the regulatory
principles of DPC proteases. We will present Top-cc as a prototypical
DPC with signiﬁcant medical implications and discuss how DPC for-
mation is exploited in cancer therapy.
2. DPC proteolysis repair
Genetic and biochemical data from bacteria and yeast led to the
long-standing assumption that DPC repair relies on canonical repair
pathways: homologous recombination (HR) and nucleotide excision
repair (NER) [9]. However, this view was challenged by the recent
discovery of DPC proteolysis (DPCP) repair [8]. The existence of DPC-
speciﬁc proteases was ﬁrst reported by the Jentsch laboratory with the
discovery of the DNA-dependent metalloprotease Wss1 (Weak Sup-
pressor of Smt3) in S. cerevisiae [10]. Wss1 cleaves DNA binding pro-
teins in vitro and Wss1 inactivation hyper-sensitizes cells to DPC-indu-
cing agents (e.g. formaldehyde). Concomitantly, a study using Xenopus
egg extract reported the existence of a replication-coupled, proteasome-
independent, proteolytic mechanism for DPC repair [11]. However, the
identity of the protease in metazoans remained elusive until very re-
cently, when several laboratories demonstrated that the DNA-depen-
dent metalloprotease for DPCs is SPRTN (also known as DVC1)
[12–16], previously described as a regulator of translesion synthesis
following UV damage [17–22]. Like its functional homolog Wss1,
human SPRTN is active in vitro against several DNA-associated proteins
[12,14,15]. SPRTN depletion in C. elegans, mouse embryonic ﬁbroblasts
(MEFs) and cultured human cells causes hypersensitivity to general (e.g.
formaldehyde) and speciﬁc (e.g. camptothecin) DPC-inducing agents
[12–15]. However, Wss1 and SPRTN are not orthologs and most of the
sequence similarity between the two proteins lies within their N-
terminal protease domains (with the conserved metalloprotease active
center HEXXH) [8,23].
2.1. ACRC (Acidic repeat containing) protein
A second potential DPC protease in higher eukaryotes might exist.
ACRC, also known as GCNA (Germ Cell Nuclear Antigen), was recently
identiﬁed as a SprT domain containing protein [24,25]. ACRC has
eluded the connection to SPRTN proteases until recently, probably due
to the prevalence of highly disordered regions within the protein
(80–100%), which make it hard to perform accurate sequence align-
ments, and due to the fact that the mouse ACRC ortholog lacks a SprT
domain [24]. Besides mice, the SprT domain is present in all metazoan
ACRC orthologs (Fig. 2).
We have performed phylogenetic analysis on multiple sequence
alignment of SprT and WLM domains in metazoans using the MAFFT
alignment algorithm [26] and Maximum Likelihood analysis (PhyML)
[27]. Another family of gluzincins, Alanyl aminopeptidases, was used
for comparison of evolutionary distance between ACRC on one side and
SPRTN and WLM families on the other. Phylogenetically, ACRC is very
close to SPRTN (Fig. 2A), while it is more distant to Wss1 orthologs of
the WLM family.
In line with the phylogenetic proximity, the 3D structure of the
protease core within the SprT domain of ACRC is very similar to that of
SPRTN (Fig. 2B). The putative protease core of ACRC includes two α-
helices bearing three zinc-binding histidines and a catalytic glutamate
residue which together form a HEXXH motif, a characteristic of all zinc-
dependent metalloproteases. The SprT domain of ACRC was modelled
according to the yeast Wss1b structure (5JIG) and the SprT domain of
SPRTN was modelled according to the abylysin template (4JIU) using
the SWISS-MODEL workspace (Fig. 2B).
Given the phylogenetic proximity of SPRTN and ACRC families and
high degree of conservation of their protease cores, it will be interesting
to determine if ACRC is proteolytically active and whether it plays a
role in DPC repair.
3. Mechanism of DPC proteolysis repair
DPCs are heterogeneous in the nature and size of crosslinked pro-
tein/s. Nevertheless, DPC proteases are capable of digesting proteins of
variable size in vitro, ranging from histones to topoisomerases, in a
DNA-dependent manner. Perhaps not surprisingly, histones and topoi-
somerases are among the most abundant DPCs in SPRTN-depleted cells
[12]. Human SPRTN associates with the replisome and removes DPCs in
front of the replication fork [12,16]. Consistently, mammalian non-re-
plicative cells are not sensitive to cross-linking agents [12]. These
evidences underscore the essential role of SPRTN in preventing re-
plication stalling upon DPC formation and account for the observed
increase in SPRTN levels in S phase (described in more detail below)
[17].
Interestingly, a replication-independent function was described for
the Drosophila SPRTN ortholog MH in male pronuclei before the ﬁrst
zygotic division; this feature has been linked to the high frequency of
topoisomerase-dependent DNA topological rearrangements at this de-
velopmental stage [25]. This study emphasizes how DPC removal is
critical during DNA transactions outside of S phase. A replication-in-
dependent function for SPRTN is also suggested by studies in post-mi-
totic C. elegans [15]. While SPRTN levels in G1 phase, albeit low, might
Fig. 1. Schematic of DPC repair pathways. A. Non-enzymatic DPCs are cleaved
by proteases and the DNA-bound peptide remnant is bypassed by translesion
synthesis (TLS) polymerases. B. Following cleavage of the bulk of the protein
component of the enzymatic DPCs, Top1- and Top2-ccs, peptide remnants can
be excised by phosophodiesterases. Alternatively, nucleases can also remove
DPCs by cleaving the DNA to which DPCs are attached.
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be suﬃcient to sustain DPC repair, it is conceivable that other proteases
(e.g. other SprT proteases, ACRC), the 26S proteasome or repair path-
ways operate when cells cannot count on SPRTN-dependent proteolysis.
Genetic studies in yeast established that NER can process DPCs in-
dependently of DPC proteolysis. This led to a model in which NER re-
moves the bulk of DPCs prior to S phase, while Wss1 or HR are needed
to circumvent the remaining, particularly toxic DPCs in S phase [10]. In
mammalian cells, however, the contribution of NER to overall DPC
removal appears to be negligible [12]. While other pathways have been
implicated in DPC repair, a deeper understanding of how they are co-
ordinated with DPCP will require further investigation.
4. Regulation of DPC proteases
DPC proteases are promiscuous, and their activity is potentially
deleterious. Therefore, their activity must be strictly regulated in order
to direct the protease to particular cross-linked proteins and to prevent
unspeciﬁc cleavage of other DNA-bound proteins, such as components
of the replisome. Research on Wss1 and SPRTN has so far highlighted
four layers of regulation: 1) cell-cycle control of protein levels; 2) DNA
binding; 3) self-cleavage and 4) post-translational modiﬁcations (PTMs)
(Fig. 3).
4.1. Cell cycle regulation
Association of SPRTN with the replisome ensures that DPC proteo-
lysis happens as the replication fork runs into DPCs. In further support
of a replication-dependent mechanism, SPRTN levels are subjected to
cell cycle regulation. SPRTN is predominantly expressed during S phase
and G2 and degraded in G1 via APC/Cdh1 [17]. The G1 degradation
might be necessary to reduce the levels of this promiscuous protease
when it is less needed. An analogous cell cycle dependency for Wss1 has
not been documented, although its levels are reportedly very low in
general [23]. DNA transactions other than replication can be similarly
aﬀected by DPCs [1]. Whether other repair pathways or other pro-
teases, especially the 26S proteasome, take over DPC repair outside of S
phase is not clear. In particular, a link between DPCP repair and tran-
scription, which is not limited to S phase, has not yet been explored.
4.2. DNA binding
A common feature of Wss1 and SPRTN is their DNA-dependent
activity: DNA acts as a scaﬀold to bring enzyme and substrate into close
proximity. Wss1 and SPRTN bind DNA via one (Wss1) or more (SPRTN)
DNA-binding motifs [10,12,14,15,28]. While being an eﬀective strategy
to contain proteolytic activity to the chromatin environment, it does not
account for how DPC proteases are restrained from processing other
essential DNA-associated proteins. The biochemical basis for the pro-
miscuity of DPC proteases could be explained by the recently published
structure of S. cerevisiae Wss1 protease domain, which shows a solvent-
exposed active site lacking a deﬁned substrate-binding cleft [29].
4.3. Self-cleavage of the DPC protease
One possible mechanism by which DPC proteases are regulated on
chromatin is via self-cleavage. For both Wss1 and SPRTN, DNA has been
shown to stimulate self-cleavage in trans [10,12–15,30]. Self-cleavage
releases C-terminal fragments from the DNA, leaving the protease do-
main intact. It is unclear whether this has any functional relevance, e.g.
increased proteolytic activity, as was suggested for Wss1 (Cysteine
switch) [30]. More likely, self-cleavage could be a protective me-
chanism that releases the active proteases from the chromatin to either
Fig. 2. A. Phylogenetic tree of SPRT and WLM families. The newly identiﬁed SPRT-like protein group, ACRC, is evolutionary close to the SPRT family. ACRC
orthologs are found in archea and eukarya, while absent in prokaryotes. Alanyl aminopeptidase family of gluzincins were used as an outgroup. Protein sequences of
SprT and WLM domains were aligned using MAFFT and the phylogenetic tree was constructed in PhyML. B. Comparison of SPRTN and ACRC SprT domains. The
protease core of ACRC is similar to that of SPRTN. The SprT domain of ACRC (in black) was modelled according to the yeast Wss1b structure (5JIG) and overlapped
with the model of the SprT domain of SPRTN protein (abylysin template, 4JIU) (in multiple colours). Protease core consists of two α-helices (in green), catalytic
glutamate (in yellow) and three zinc binding histidines (in red). Homology models were created in SWISS-MODEL workspace and visualized in UCSF Chimera.
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preserve non-covalently associated proteins or terminate proteolysis
after DPC removal. Consistent with this model is the observation that
the auto-cleavage products of SPRTN cannot bind DNA [15]. Im-
portantly, self-cleavage might partially explain how cells preserve
functional DNA-associated proteins from proteolysis, but does not
clarify how SPRTN substrate speciﬁcity is achieved. Thus, other reg-
ulatory mechanisms must exist.
While self-cleavage is stimulated in vitro by both single- and double-
stranded DNA [10,12,14,15,30], proteolytic processing of substrates
might be preferentially fostered by single-stranded DNA [15]. In line
with this observation, single-stranded DNA forms during replication
whenever the replicative polymerase stalls behind a DPC while the
helicase progresses past the lesion [1]. However, this model does not
account for those large DPCs that will block helicase progression as
well. Therefore, while intriguing, this model is not deﬁnitive and dis-
agrees with studies showing that dsDNA and ssDNA are both equally
eﬀective in stimulating substrate cleavage and auto-cleavage [12–14].
Thus, more work is needed to explain how DPC proteases are activated
when the replication fork encounters a DPC.
4.4. Post-translational modiﬁcations
SPRTN is mono-ubiquitylated and its recruitment to the chromatin
coincides with its de-ubiquitylation [15]. This so-called ubiquitin
switch model predicts that SPRTN is kept in an ‘inactive’ conformation
by virtue of the interaction between the SPRTN ubiquitin-binding do-
main (UBZ) and the modifying ubiquitin; deubiquitylation by a so-far
elusive deubiquitinating enzyme would thus ‘activate’ SPRTN upon
DPC formation.
In addition to ubiquitylation, several screening studies have iden-
tiﬁed numerous SUMOylation sites on SPRTN. Notably, modiﬁcation by
SUMO is increased after stress is applied (e.g. proteasomal inhibition or
replication stress) [31–34]. Thus, it is tempting to speculate that cel-
lular stress and/or DNA damage trigger PTMs that activate SPRTN.
On the other hand, PTMs could be a way to direct DPC proteases to
their substrates or sites of damage. In Xenopus egg extract DPC pro-
cessing requires free ubiquitin [11]. This raises the intriguing possibi-
lity that ubiquitin labels DPCs for SPRTN recruitment. Some groups
have shown that SPRTN binds ubiquitylated PCNA (Rad18 pathway) at
stalled replication forks after UV damage [19–22]. Although this ob-
servation remains controversial [17,18], genetic data would suggest
that a similar (Rad18-dependent) mechanism applies to DPC-dependent
damage [14]. Consistently, Rad18-mediated PCNA ubiquitylation also
occurs upon accumulation of ssDNA at stalled replication forks [35,36].
The regulation by PTMs might diﬀer in lower eukaryotes, where
SUMO rather than ubiquitin might recruit the DPC protease to the site
of protein crosslinks. Yeast Wss1 binds SUMO via two C-terminal
SUMO-binding motifs (SIMs) which are required for resistance to for-
maldehyde [10]. The fact that Wss1 and SPRTN might be subjected to
diﬀerent modes of regulation is also suggested by the experimental
evidence that plasmid-borne SPRTN cannot rescue the camptothecin
sensitivity of a yeast wss1 tdp1 double deletion mutant [13].
Overall, it is becoming clear that DPC protease activity is subjected
to several layers of regulation; however, the regulatory modes are far
from being completely deciphered and are a matter of future in-
vestigations.
5. DPC proteolysis repair of Top1- & Top2-ccs
Perhaps the most biologically and therapeutically relevant DPCs are
Topoisomerase 1 and 2 cleavage complexes (Top-ccs). Upstream pro-
teolysis of Top-ccs by DPC proteases has emerged as an important
component of Top-cc repair [12,16]. When topoisomerases cleave DNA
to resolve topological stress they form a catalytic intermediate, known
as a Top-cc, in which a tyrosine in their active site is covalently bound
to the phosphate group of a nucleotide. Top1 cleaves one strand of
DNA, and swivels the broken DNA strand around the unbroken strand
before re-ligation. Top1 can also form double-strand breaks (DSBs) if it
cleaves opposite a DNA lesion or if a Top1-cc is encountered by a re-
plication fork (leading to a single-ended DSB) [37]. Top2, meanwhile,
always generates DSBs and re-ligates both DNA strands. Top-ccs are
normally transient but can become trapped when a topoisomerase
cleaves near DNA alterations (e.g. nicks, breaks, abasic sites) or upon
exposure to endogenous or exogenous crosslinking agents [6].
Top-ccs disrupt essential DNA processes, including DNA replication
and transcription, and can therefore have pathogenic or cytotoxic
consequences. For example, both Top1- and 2-ccs are associated with
neurodegenerative disorders [38,39]. Furthermore, the widely-used
anti-cancer drugs, camptothecin (CPT) and etoposide (ETO), kill cancer
cells by trapping Top1- and 2-ccs, respectively. ETO can also induce
chromosomal translocations associated with secondary malignancies,
demonstrating the tumorigenic potential of Top-ccs [40,41].
Top-ccs were previously known to be repaired by two diﬀerent
pathways operating on the DNA adjacent to or linked to the trapped
cleavage complex, i.e.:
1) Excision by the phosphodiesterases TDP1 and TDP2: TDP1 and
TDP2 hydrolyse the phosphodiester bonds linking Top-ccs to DNA.
TDP1 and TDP2 preferentially resolve Top1- and 2-ccs, respectively.
2) DNA cleavage by endonucleases: Top-ccs can be removed by en-
donucleases that cleave the DNA ﬂanking a Top-cc. Many nucleases
have been implicated in this process, including XPF-ERCC1 (for
Top1-ccs), the MRN complex, and CtIP [42–44].
However, a novel mechanism of Top-ccs repair has been identiﬁed:
3) DPC proteolysis repair has recently emerged as a key component
Fig. 3. Summary of regulation layers of DPC proteases. A. SPRTN is degraded in
G1 phase after ubiquitylation by APC/Cdh1. This ensures the levels of the
protease are low when its activity is less needed. B. Wss1 or SPRTN (in red) are
recruited to DNA for cleavage of the substrate (DPC; in brown): this ensures that
their protease activity is restricted to the chromatin environment. C. DNA also
stimulates Wss1 or SPRTN self-cleavage: this helps to prevent unscheduled
proteolysis of DNA-associated proteins. D. Left, SPRTN is modiﬁed by ubiquitin
and de-ubiquitylated upon DPC formation induced by formaldehyde (FA).
Right, DPCs might be modiﬁed by ubiquitin (or ubiquitin-like proteins) to re-
cruit DPC proteases to the site of damage.
Colour Code: Red: Wss1 or SPRTN protease; Brown: DPC; Green: Ubiquitin or
Ubiquitin-like protein.
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of the response to Top-ccs. Various lines of investigation posited that
such a mechanism must exist, primarily to allow phosphodiesterases
access to the phosphotyrosyl bond concealed inside a Top-cc.
Indeed, TDP1 and TDP2 resolve Top-ccs in vitro after the Top-cc is
subjected to heat denaturation or proteolytic digestion in most cases
[45–47].
A role for proteases in processing the bulk of the protein compo-
nents of Top-ccs was ﬁrst demonstrated in yeast [10]. It was found that
cells lacking TDP1 relied on the protease activity of Wss1 for their
survival, especially in the presence of CPT. SPRTN counteracts Top1-
and 2-ccs even in the absence of exogenous DPC-inducing agents and
SPRTN depletion alone hypersensitizes cells to both CPT and ETO [12].
Notably, hypomorphic SPRTN mice accumulate Top1ccs, particularly in
the liver, and develop liver tumours at an early age [16]. Whereas Wss1
and TDP1 act in distinct pathways to repair Top1ccs, SPRTN appears to
act upstream of TDP1, at least in human cells [12]. The 26S proteasome
is also likely to be involved in Top1/2 processing, however, in vivo its
contribution is usually only observed after treatment with high doses of
CPT and ETO [46,48,49].
The question of how DPCs are distinguished from essential proteins
that are tightly bound to chromatin has not been fully addressed, but, at
least in Top-cc repair, post-translational modiﬁcations are proposed to
drive this distinction. Both Top1- and 2-ccs are extensively ubiquity-
lated and SUMOylated in both yeast and humans and both of these
modiﬁcations are induced by treatment with Top1- or Top2-speciﬁc
poisons [50–54].
Initial indications that SUMO might initiate Top-cc repair came
from yeast which were hypersensitive to CPT when the E2 SUMO
conjugating enzyme/ligase, Ubc9, was deleted [50]. In mice and hu-
mans, ATM regulates the SUMO/ubiquitin-dependent turnover of
Top1ccs, and Top1cc accumulation may contribute to the neuro-
pathology of ataxia telangiectasia patients [55,56]. In yeast, both Top1-
and 2-ccs are subject to SUMOylation by E3 SUMO ligases of the PIAS
family and are then ubiquitylated by SUMO-targeted ubiquitin ligases
(STUbLs) [57,58]. For both Top1- and 2-ccs, this ubiquitylation is
thought to recruit Cdc48 (p97 in humans), a hexameric ATPase capable
of unfolding substrates, thereby facilitating their removal from chro-
matin and promoting their degradation by the 26S proteasome [57,59].
A recent report has placed further emphasis on the role of SUMO in
the upstream processing of Top-ccs [60]. The E3 SUMO ligase ZNF451
modulates proteasome-independent Top2cc repair via two mechanisms.
Firstly, by directly binding Top2-ccs, ZNF451 induces a conformational
change that facilitates TDP2′s access to the phosphotyrosyl bond that
links Top2 to DNA. Secondly, ZNF451 conjugates SUMO-2/3 chains to
Top2-ccs, which serve as a signal for the recruitment of TDP2. Further
studies will hopefully address the interplay and relative contribution of
each repair pathway and PTM to counteracting Top-cc-induced genome
instability.
It seems plausible that PTMs could be important either for recruiting
DPC proteases or for stimulating their protease activity in vivo. Indeed,
Wss1, SPRTN and ACRC all possess SIMs [24]. Wss1 variants which
cannot bind SUMO fail to fully rescue the viability of Wss1-deﬁcient
cells [10]. Recent reports suggest that SPRTN’s UBZ, while required for
its role in the response to UV-induced damage, is not necessary for DPC
proteolysis [15–18].
Furthermore, both Wss1 and SPRTN have motifs that enable them to
interact with p97. Wss1 requires its interaction with Cdc48 to coun-
teract CPT-induced toxicity [10]. Cdc48 also promotes the degradation
of SUMO/ubiquitylated Top2-ccs via the 26S proteasome [57]. On the
other hand, SPRTN’s protease domain alone can rescue the DPC repair
defects of SPRTN deﬁcient cells [15,16]. However, these experiments
tend to involve overexpressing SPRTN’s protease domain which could
obscure the role of other domains (e.g. SHP, and thus p97) in the subtle
ﬁne-tuning of SPRTN activity.
As mentioned above, SPRTN expression is mainly restricted to S
phase and coupled to replication [12]. Wss1 also apparently acts on
DPCs that have escaped repair by NER and entered S phase. However,
DPCs are also potentially very toxic in other cell cycle stages, due for
example to interference with transcription, as demonstrated by the
neuronal disorders resulting from TDP1 and TDP2 mutations. It is
therefore likely that there exist other factors acting upstream of TDP1
and TDP2 in diﬀerent phases of the cell cycle.
6. DPC proteolysis repair in disease & cancer therapy
6.1. DPCP repair defect causes accelerated ageing and liver cancer
In humans, SPRTN mutations cause a medical condition known as
SPARTAN syndrome or Ruijs-Aalfs syndrome (RJALS) characterized by
premature aging, early onset hepatocellular carcinoma and chromo-
somal instability [61,62]. RJALS patient-derived cells display an accu-
mulation of DPCs and hypersensitivity to DNA-protein crosslinking
agents, along with DNA replication stress and an increased frequency of
DSBs [12,13,61]. These defects can be reproduced in cultured cells
upon ectopic expression of disease-associated SPRTN mutants variants
[12,61]. SPRTN knock-out in mice is embryonic lethal, but conditional
knock-out in MEFs causes replication defects and genomic instability
[63]. Additionally, SPRTN hypomorphic mice recapitulate RJALS pa-
tient phenotypes, namely progeroid phenotypes and liver tumours [16].
Overall, these phenotypes establish an unequivocal link between DNA
replication-coupled DPC removal and protection from accelerated
ageing and cancer.
6.2. Therapeutic potential for intervention on DPCP repair
The toxic potential of DPCs is exploited in cancer therapy, where
drugs that induce DPCs are already widely used to kill cancer cells.
Indeed, nearly half of all currently-used anti-cancer regimens consist of
drugs that trap Top-ccs [64]. Camptothecins bind the interface between
the DNA and Top1: they trap Top1ccs as soon as they form, preventing
re-ligation of the broken DNA strand. Camptothecins are eﬀective
against a variety of diﬀerent types of cancers and are routinely used to
treat metastatic colorectal cancer [65]. A new class of non-camp-
tothecin derived compounds, the indenoisoquinolines, are also inter-
facial Top1cc inhibitors but exhibit many improved features. For in-
stance, they are less rapidly metabolised by cells than camptothecins
and, unlike camptothecins, they induce Top1ccs which persist even
after drug withdrawal. Indenoisoquinolines are showing promising re-
sults in clinical trials for the treatment of solid tumours and lymphomas
[66] (http://clinicaltrials.gov/show/NCT01245192).
Most clinically-used Top2-targetting drugs trap Top2-ccs, including
etoposide, doxorubicin (and other anthracyclines), and mitoxanthrone,
but do so via diﬀerent mechanisms. For example, doxorubicin inter-
calates in DNA and stabilises Top2ccs, whereas etoposide is speciﬁc for
the Top2-DNA interface. Cancers with Top2a gene ampliﬁcations (e.g.
Her2-positive breast cancers) often exhibit enhanced sensitivity to
various Top2 poisons [40].
As acquired resistance to topoisomerase-trapping drugs is common,
much attention has been placed on targeting factors which modulate
sensitivity to these drugs. High-throughput screens have identiﬁed
many promising hits such as those which inhibit TDP1 by mimicking its
phosphotyrosine substrate [67]. These inhibitors are likely to be of
signiﬁcant value in cancers, such as non-small cell lung cancers
(NSCLCs), where TDP1 is reported to be overexpressed [68]. Deaza-
ﬂavin inhibitors of TDP2 also show promising selectively and potency
in pre-clinical trials [69].
The covalent trapping of other DNA enzymes underlies the eﬀec-
tiveness of other chemotherapeutic agents, such as 5-aza-2′-deox-
ycytidine (5-aza-dC), which is used to treat myelodysplastic syndromes
and acute myeloid leukaemia [70]. 5-aza-dC is a cytosine analogue that
is incorporated into DNA. While attempting to methylate the 5-aza-dC
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molecule, DNMT1 is trapped leading to loss of global DNA methylation
and cell death [71].
DPC induction is increasingly being recognized as an important
mode of action for other anti-cancer drugs that are already in clinical
use. For example, one way in which platinum-based agents, such as
cisplatin and oxaliplatin, exert their cytoxicity is by inducing protein
crosslinking to platinum-DNA complexes. This includes the crosslinking
of histones, but also of potentially any protein in the vicinity of DNA.
Notably, there is some evidence indicating a positive correlation be-
tween the clinical eﬃcacy of platinum compounds and the extent to
which they induce DPCs [72,73]. Another example is PARP trapping by
PARP inhibitors. The eﬀectiveness of PARP inhibitors (PARPi) has been
demonstrated to correlate better with their ability to trap PARP on DNA
than it does with their ability to inhibit PARP catalytic activity [74]. An
understanding of how PARP-DNA complexes and protein-platinum-
DNA complexes are resolved could help improve treatment for PARPi/
Platinum-resistant breast and ovarian cancers as well as other PARPi
resistant cancers.
Targeting DPC repair pathways could be beneﬁcial for cancer
therapy with currently ineﬀectual treatment regimens. For example,
inhibitors of DPC repair could sensitize hypoxic tumours following the
IR treatment, given that IR mainly induces DPC formation in hypoxic
tissues [75].
7. Conclusion and perspectives
The emergence of DPC proteases has exciting implications for
cancer therapy and ageing. The importance of these enzymes will sti-
mulate further work into their physiological roles and modes of reg-
ulation. In particular, it will be important to address how their pro-
miscuous activity is targeted to speciﬁc substrates and how DPC repair
pathway choice is made. Structural insights into SPRTN substrate
binding and speciﬁcity could facilitate the development of drugs that
target its protease activity. While the contribution of DPCs to carcino-
genesis has attracted much attention, their role in ageing requires fur-
ther elucidation. Unravelling these questions will have signiﬁcant ra-
miﬁcations for our understanding human diseases and the development
of eﬀective therapies.
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